Fate Therapeutics FATE reported a loss of 31 cents per share (excluding impairment loss) in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 44 cents. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback